Abstract
Background: Aromatase inhibitor (AI) was received by breast cancer women with estrogen receptor-positive. The estrogen is the main stimulator for receptor-positive breast cancer cells development and growth, the adjuvant hormone ablation targeting estrogen can decrease the likelihood of cancer recurrence and prolong cancer-free survival. Objective: To determine the effect of this therapy on bone mineral density of women who received it. Patients and Methods: It was identified 100 women with local or regional breast cancer diagnosed and who received AI therapy in the January 2022 to February 2023 from Baqubah teaching hospital/Oncology Centre. It was used DEXA scan to determine the bone minerals density of 50 women after different years from receiving hormonal therapy and other 50 breast cancer women before receiving hormonal therapy. Results: It was shown that there is a significant difference (p<0.0001) in the spine and hip density of breast cancer women who received AIs compare with the bone density of other breast cancer women who did not receive it. Conclusion: It can conclude that Als plays an essential role for osteoporosis that reduce the quality of health and increase the risk of fraction in the breast cancer women. Keywords: Breast cancer, Hormonal therapy, Bone mineral, Osteoporosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.